Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

Description

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

Conditions

Obesity, Breast Cancer Risk

Talk to us

Study Overview

On this page

Study Details

Study overview

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women with Obesity and Other Risk Factors for Breast Cancer

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Kansas City

University of Kansas Medical Center, Kansas City, Kansas, United States, 66160

Westwood

University of Kansas Medical Center Breast Cancer Prevention Center, Westwood, Kansas, United States, 66208

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * • BMI 30-45 kg/m2
  • * Female
  • * Insurance approved or likely approved for tirzepatide clinical use \*
  • * Additional risk factors for breast cancer other than obesity (any one or more) First or second degree with breast cancer Known high density on mammogram (heterogenous or extremely dense) Prior biopsy showing atypical hyperplasia or LCIS Prior treated DCIS Known carrier breast cancer predisposition gene mutation or known mutation in family member .
  • * • Subglandular breast implants (women with subpectoral implants are eligible if C cup or greater; breast can easily be pulled off the chest wall; and with approval of PI)
  • * Clinical contra-indication to incretin mimetics
  • * Insurance/third party has denied coverage and participant does not wish to do self-pay.
  • * Child-bearing potential and not on contraceptives
  • * Prior invasive breast cancer
  • * Currently taking any of the following medications: insulin, tamoxifen, raloxifene, letrozole, arimidex, exemestane, incretin mimetics.

Ages Eligible for Study

40 Years to 64 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Kansas Medical Center,

Carol J Fabian, MD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Study Record Dates

2025-12